Myriad Genetics | MYGN - Cash And Equivalent


Myriad Genetics reported $115.2M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Agilent USD 1.81B 49M Mar/2026
Becton, Dickinson and Co. USD 708M 105M Jun/2026
Bio-Rad Laboratories USD 517M 9.8M Jun/2026
Bruker USD 184.9M 51.5M Jun/2026
Danaher USD 4.35B 1.35B Jun/2026
Illumina USD 1.09B 329M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Mettler Toledo International USD 51.38M 9.19M Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
OraSure Technologies USD 160.58M 16.38M Jun/2026
Pacific Biosciences Of California USD 61M 4.73M Jun/2026
Quest Diagnostics USD 626M 233M Jun/2026
Quidel USD 123.4M 17M Jun/2026
Repligen USD 606.78M 24.13M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Standard Biotools USD 265.77M 147.56M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Veracyte USD 299.52M 36.38M Jun/2026
Waters USD 539M 77M Jun/2026